— Early sign of Alzheimer's reversed in lab — One of the earliest known impairments caused by Alzheimer's disease - loss of sense of smell - can be restored by removing a plaque-forming protein in a mouse model of the disease,…
— Parental controls on embryonic development? — When a sperm fertilises an egg, each contributes a set of chromosomes to the resulting embryo, which at these very early stages is called a zygote. Early on, zygotic genes are inert,…
— Newly discovered heart stem cells make muscle and bone — Researchers have identified a new and relatively abundant pool of stem cells in the heart. The findings in the December issue of Cell Stem Cell, a Cell Press publication, show that…
— BUSM researchers develop blood test to detect membranous nephropathy — Research conducted by a pair of physicians at Boston University School of Medicine (BUSM) and Boston Medical Centre (BMC) has led to the development of a test that can help diagnose…
— New hip implants no better than traditional implants — New hip implants appear to have no advantage over traditional implants, suggests a review of the evidence published on bmj.com today…
— Action needed to improve men's health in Europe — Policies aimed specifically at men are urgently needed to improve the health of Europe's men, say experts on bmj.com today…
— Probiotics reduce infections for patients in intensive care — Traumatic brain injury is associated with a profound suppression of the patient's ability to fight infection. At the same time the patient also often suffers hyper-inflammation, due…
— High blood sugar levels in older women linked to colorectal cancer — Elevated blood sugar levels are associated with an increased risk of colorectal cancer, according to a study led by researchers at Albert Einstein College of Medicine of Yeshiva University.…
— Engineered botulism toxins could have broader role in medicine — The most poisonous substance on Earth - already used medically in small doses to treat certain nerve disorders and facial wrinkles - could be re-engineered for an expanded role in helping…
TU Delft to help cancer patients
TU Delft's nuclear research reactor will be used as a back-up facility for the production of the radioactive isotope molybdenum-99, when supplies run out. Molybdenum-99 is widely used in hospitals in order to locate cancer. The substance is regularly in short supply because there are only five large commercial producers worldwide, and they all produce using older reactors. TU Delft announced earlier this year that its reactor could act as back-up facility when supplies run out. The Ministry of Health, Welfare and Sport has accepted this offer and asked the university to adapt its reactor for the production of this isotope.
Medical isotopes are widely used in hospitals to help diagnose diseases, particularly cancer. Because there are only five commercial producers worldwide, and these use older reactors, ensuring an adequate and secure supply of medical isotopes has become a problem in recent years. In the future, TU Delft's nuclear research reactor will be used as a back-up facility for the high flux reactor in Petten. The reactor in Delft will be capable of supplying the weekly demand for molybdenum-99 in the Netherlands. However, supplies of the isotopes produced in the Netherlands will not necessarily have to be used in the Netherlands.
Molybdenum-99 is used in the pharmaceutical industry to produce 'molybdenum-99 / technetium-99m generator.' When a doctor suspects that a patient is suffering from a tumour, he/she will inject technetium-99m from the generator into the patient, together with certain substances that will attach themselves to that type of tumour. The technetium-99m emits photons (gamma radiation) which are then detected by special equipment outside the body. In this way, it is possible to make an image of the tumour and thereby locate the tumour within the body. This is essential in order to provide the optimum treatment.
The Delft research reactor will now be adapted so that it can start to produce molybdenum-99. As soon as safety standards have been met and approved, the reactor will be able to produce molybdenum when required. 'The Reactor Institute Delft wishes to improve the care for cancer patients by helping to ensure that there are sufficient supplies of isotopes for medical use,' says Prof. Tim van der Hagen, director of the Reactor Institute Delft.
TU Delft's research reactor is used for scientific research in the fields of health, energy and materials. The Oyster Programme (which stands for 'Optimised Yield - for Science, Technology and Education - of Radiation') will enable the reactor to meet new scientific challenges and respond to societal issues even more accurately and flexibly. The production for molybdenum-99 is a good example of this. The programme will enable the production of molybdenum to be increased because it will make more neutrons available.
Or subscribe for our Newsletter, a free e-mail publication. It is published practically every day.
March into spring with National Nutrition Month
A ray of sunshine in the fight against cancer
Chemical chaperone could open door to treatment of neurological disorder
Targeting astrocytes slows disease progression in amyotrophic lateral sclerosis